Sign In

Akseli Hemminki

CEO of TILT Biotherapeutics, Professor of Oncology

Akseli Hemminki is a prominent figure in the field of oncology with extensive experience in both academic and industry roles. He currently holds multiple positions:

Professional Roles

  • Professor of Oncology at the University of Helsinki1
  • CEO of TILT Biotherapeutics, a company focused on cancer immunotherapy23
  • Previously served as Head of Department at Helsinki University Hospital Comprehensive Cancer Center1

Academic Background

Hemminki has a strong educational foundation, having studied at:

  • University of Helsinki
  • Helsinki University Central Hospital
  • University of Alabama at Birmingham1

Research and Expertise

Akseli Hemminki is a renowned researcher in the field of oncology:

  • He has published hundreds of papers in the field of oncology4
  • Has treated almost 300 patients with 10 different oncolytic viruses4
  • Founded Oncos Therapeutics, where he served as a scientific founder and board member1

Current Focus

At TILT Biotherapeutics, Hemminki is leading efforts to advance cancer immunotherapy:

  • The company has recently raised significant funding ($23,611,000) to support their research and development4
  • They are working on innovative approaches to cancer treatment, likely involving oncolytic viruses based on Hemminki's expertise

Akseli Hemminki's career demonstrates a strong commitment to advancing cancer treatment through both academic research and practical applications in the biotech industry.

Related Questions

What are Akseli Hemminki's main research interests?
How has Akseli Hemminki contributed to the field of oncology?
What is the focus of TILT Biotherapeutics under Akseli Hemminki's leadership?
Can you provide examples of Akseli Hemminki's notable publications?
What are the key achievements of Akseli Hemminki in his career?
Akseli Hemminki
Akseli Hemminki, photo 1
Akseli Hemminki, photo 2
Add to my network

Location

Helsinki, Uusimaa, Finland